
Understand the EAU's low testosterone threshold, relevant symptoms and why repeat testing, sleep, fasting and illness matter when interpreting results.

Low testosterone means that a blood test has measured testosterone below the threshold being used to assess it. Hypogonadism is a clinical diagnosis considered when compatible symptoms or signs occur alongside consistently low testosterone.
This article provides general information and is not medical advice. A qualified clinician should interpret personal symptoms and test results and decide whether further evaluation or treatment is appropriate.
The European Association of Urology (EAU) gives 12 nmol/L as a total-testosterone threshold for diagnosing late-onset hypogonadism. It recommends repeating results below that level on separate occasions and interpreting them alongside symptoms and the clinical profile.
This is a guideline-specific diagnostic threshold rather than a universal normal range. It should not be treated as a complete laboratory reference interval with lower and upper limits. The important distinction is between a measured concentration and the clinical judgment about what that concentration means.
Biologically, a testosterone result describes the hormone concentration in the blood sample. A lower concentration establishes what was measured at that moment. Establishing whether it represents persistent testosterone deficiency requires the rest of the clinical assessment.
EAU guidance bases diagnosis on compatible symptoms or signs together with consistently low morning testosterone confirmed on at least two occasions. Those measurements should use a reliable laboratory assay and fasting conditions. The guideline recommends confirmation before testosterone therapy is started.
Repeat testing addresses persistence. A clinician is checking whether the low finding remains present under appropriate sampling conditions rather than assuming that the first sample represents a man's usual level.
The practical question is therefore not simply whether a report carries a low flag. It is whether the symptom history and appropriately collected measurements form a consistent clinical picture.
An assay is the laboratory method used to measure testosterone. The EAU identifies LC-MS/MS as the most accurate method for sex-steroid evaluation. It also notes that standardized automated immunoassays for total testosterone correlate well with that method.
This distinction does not mean every result obtained by another method is unsuitable. It means the laboratory method belongs in the interpretation. When results come from different laboratories or methods, a clinician can assess how directly they can be compared.
The EAU recommends considering sex hormone-binding globulin (SHBG) measurement and free-testosterone calculation when total testosterone is near the lower limit. These assessments may also be relevant when a condition could alter SHBG.
That is a targeted follow-up consideration rather than a requirement for every man. The decision depends on why the total-testosterone result needs further interpretation. Understanding why SHBG enters the discussion can help make that conversation more focused.
Method matters for free testosterone as well. The EAU identifies equilibrium dialysis as the most accurate measurement method and advises against some direct free-testosterone immunoassays. A calculated result and a directly measured result therefore deserve attention to how each was obtained.
When testosterone is found to be pathologically low, the EAU recommends further evaluation with luteinising hormone (LH) and follicle-stimulating hormone (FSH) to help distinguish types of hypogonadism. It also recommends prolactin measurement in specified clinical circumstances. Confirming the finding and investigating its possible cause are related but separate parts of the evaluation.
The EAU identifies reduced libido and fewer spontaneous or morning erections among the more specific symptoms associated with hypogonadism. It also lists fatigue and low energy alongside sleep problems and concentration difficulties as less specific symptoms.
For adult men, the distinction matters because these complaints do not all carry the same diagnostic weight. A change in sexual desire may be relevant to a testosterone assessment. Persistent tiredness also deserves attention, but it does not identify a hormonal cause by itself.
The symptom patterns worth discussing include:
The EAU cautions that symptoms associated with hypogonadism are not exclusive to it. A symptom list is therefore not a diagnostic scoring system. The same assessment must account for the blood results and the circumstances in which they were collected.
A useful clinical discussion describes what has changed rather than assigning the change to testosterone in advance. Testostra's explanation of how symptoms fit into a hormone assessment provides additional context for that distinction.
The EAU identifies several physiological and sampling factors that influence testosterone interpretation. These are reasons to review the circumstances of a result rather than treating every blood draw as equivalent.
These factors explain why preparation and health context are part of interpretation. They do not provide a formula for correcting an individual result. A clinician should not have to guess whether a sample was fasting or whether the usual morning recommendation matched the person's sleep schedule.
For a results review, relevant information includes the collection time and fasting status. Sleep before sampling and any acute illness also matter. Shift work should be part of that discussion when it changes the usual relationship between sleep and clock time.
The clinician can then decide whether the existing measurements are suitable for comparison or whether another sample is appropriate. A fuller explanation of timing and preparation for comparable blood draws can help readers understand why these details are recorded.
This is a testing-context discussion rather than a lifestyle treatment plan. The evidence here supports attention to sleep-related timing and fasting conditions alongside illness status. It does not justify assuming that changing one of those factors will resolve a person's symptoms or establish the reason for a low result.
Ask your physician: “Do my symptoms fit testosterone deficiency? Were my samples timed appropriately for my sleep and taken fasting? Should the low result be repeated? Would SHBG, free testosterone or tests for possible causes clarify the findings?”
Numerical cutoffs simplify testosterone reports while leaving important questions about related biomarkers unresolved. Testostra helps readers make sense of SHBG alongside the distinction between total and free testosterone through evidence-led education that keeps individual medical decisions with qualified care.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra